| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Zaire ebolavirus |
| Clinical data | |
| Trade names | Ebanga |
| Other names | Ansuvimab-zykl, mAb114 |
| License data | |
| Routes of administration | Intravenous |
| Drug class | Monoclonal antibody |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6368H9924N1724O1994S44 |
| Molar mass | 143950.15 g·mol−1 |
Ansuvimab, sold under the brand name Ebanga, is a monoclonal antibody medication for the treatment of Zaire ebolavirus (Ebolavirus) infection.[1][2]
The most common symptoms include fever, tachycardia (fast heart rate), diarrhea, vomiting, hypotension (low blood pressure), tachypnea (fast breathing) and chills; however, these are also common symptoms of Ebolavirus infection.[1]
Ansuvimab was approved for medical use in the United States in December 2020.[1][2][3] It is on the World Health Organization's List of Essential Medicines.[4]
- ^ a b c d "FDA Approves Treatment for Ebola Virus". U.S. Food and Drug Administration. 21 December 2020. Retrieved 23 December 2020.
This article incorporates text from this source, which is in the public domain.
- ^ a b "Ridgeback Biotherapeutics LP Announces the Approval of Ebanga for Ebola" (Press release). Ridgeback Biotherapeutics LP. 22 December 2020. Retrieved 23 December 2020 – via Business Wire.
- ^ "Drug Trials Snapshot: Ebanga". U.S. Food and Drug Administration (FDA). 21 December 2020. Retrieved 13 January 2021. This article incorporates text from this source, which is in the public domain.
- ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
